McMurray et al. demonstrated a 20% relative risk reduction in cardiovascular-related death and a 21% relative risk reduction in hospitalization secondary to heart failure when treated with sacubitril/valsartan vs. enalapril in patients with heart failure with a reduced ejection fraction (HFrEF) [1], highlighting its therapeutic superiority over angiotensin-converting enzyme inhibitors (ACE-Is) in the HFrEF population. The gene discussed is ACE; the disease is heart failure.